Treatment
PD-1 monoclonal antibody clinical trials
We’re tracking 84 recruiting studies that include PD-1 monoclonal antibody, each written for real people, not researchers, below.
Recruiting studies
- NCT07416890RecruitingPhase 2
Study of thiotepa, pirtobrutinib, and sintilimab for CNS lymphoma
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
Hangzhou, ZhejiangAges 18–80 - NCT05916248RecruitingEarly Phase 1
mRNA vaccine plus pembrolizumab for advanced solid tumors
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06923345RecruitingPhase 2
Modified long-course radiation and chemo with immunotherapy for rectal cancer
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
Guangzhou, GuangdongAges 18–75 - NCT07138755RecruitingPhase 2
PD-1, chemo, and adaptive radiation for stage 3 lung cancer
This study tests if adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy and specially planned radiation works better for stage 3 lung cancer that cannot be surgically removed. It may be an option if you have not had previous treatment for this cancer.
Changsha, HunanAges 18–75 - NCT06980155RecruitingEarly Phase 1
Personalized vaccine with or without toripalimab to prevent AML relapse
This trial tests a personalized cancer vaccine, alone or with an immunotherapy drug called toripalimab, to help keep acute myeloid leukemia (AML) in remission. It is for people who have finished initial treatment, are in remission, but still have some leukemia cells remaining (MRD positive) and have a specific NPM1 gene mutation.
ShanghaiAges 18 years+ - NCT06831175RecruitingPhase 2
PD-1 inhibitor combined with apatinib and mitotane for advanced adrenal cancer
This trial tests a new combination of drugs (PD-1 inhibitor, apatinib, and mitotane) for people with advanced adrenal cortical carcinoma that cannot be removed by surgery. The goal is to see if this combination is safe and effective for those who have not yet received standard first-line treatment.
Chengdu, SichuanAges 18–70 - NCT06980038RecruitingPhase 2
Testing two immunotherapy drugs before surgery for advanced head and neck cancer
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
Irvine, CaliforniaAges 18 years+ - NCT06963814RecruitingPhase 1
HC006 with a PD-1 inhibitor for advanced solid tumors
This trial tests a new drug called HC006 combined with a standard immunotherapy (PD-1 inhibitor) for people with advanced solid tumors. It aims to see if the combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Miami, FloridaAges 18 years+ - NCT04165772RecruitingPhase 2
Dostarlimab for locally advanced mismatch-repair deficient solid tumors
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hartford, ConnecticutAges 18 years+ - NCT05512351RecruitingPhase 2
Immunotherapy plus low-dose Avastin for recurrent oligodendroglioma
This Phase 2 trial tests an immune treatment (sintilimab, an anti–PD-1 antibody) together with low-dose bevacizumab (Avastin) to treat oligodendroglioma that has come back, including cases detected by tumor DNA in body fluid. It aims to slow or control tumor growth and help reduce symptoms by targeting both the tumor and its blood supply.
Zhengzhou, HenanAges 18 years+ - NCT07699939RecruitingPhase 2
Perioperative immunotherapy plus chemo for advanced gastric cancer
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Chiba, ChibaAges 18–80
Common questions
- Are there clinical trials studying PD-1 monoclonal antibody?
- Yes. Clin2 currently lists 84 recruiting studies that include PD-1 monoclonal antibody, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a PD-1 monoclonal antibody trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is PD-1 monoclonal antibody an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether PD-1 monoclonal antibody or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.